You are here

Triagonist Peptide Therapeutics for Neuroprotection

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41GM142448-01A1
Agency Tracking Number: R41GM142448
Amount: $259,613.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 300
Solicitation Number: PA20-265
Timeline
Solicitation Year: 2020
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-09-25
Award End Date (Contract End Date): 2022-09-24
Small Business Information
254 UPLAND RD, #3
Cambridge, MA 02140-3605
United States
DUNS: 080572483
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KRISHNA KUMAR
 (617) 627-5651
 krishna.kumar@tufts.edu
Business Contact
 VITTORIO MONTANARI
Phone: (617) 564-3586
Email: vittorio.montanari@icloud.com
Research Institution
 TUFTS UNIVERSITY MEDFORD
 
136 HARRISON AVENUE
BOSTON, MA 02111-1817
United States

 Nonprofit College or University
Abstract

Project Summary
Morbidity associated with neuronal degeneration and dysfunction poses an increasing public
health burden. Among the wide range of etiologies that result in neuronal dysfunction, including
chronic conditions such as Alzheimer’s and Parkinson’s disease and vascular dementias, one
major cause that has been largely unnoticed but is increasingly recognized as a major concern is
traumatic brain injury (TBI). Even mild TBI (mTBI), which is highly prevalent and underestimated
in sport related injuries especially in American football and soccer and in the military, can have
persistent, and sometimes progressive, long-term debilitating effects. There is now evidence that
even a single traumatic brain injury, beyond causing reversible short-term defects, can precipitate
or accelerate age-related other neurodegenerative disease entities as noted above. The unmet
need is to develop a neuroprotective or disease-modifying therapy that can slow or halt disease
progression.
Recently, a synthetic monomeric peptide compound that acts as an agonist for three separate
receptors (“triagonist”), GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent
insulinotropic polypeptide receptor) and the glucagon receptor that control and direct glucose
metabolism, seems to have beneficial neurotrophic and neuroprotective effects useful for
conferring neuroprotection and mitigating the behavioral deficits in animal models of TBI and
Alzheimer’s disease.
We have invented chemical modifications at the N-terminal end of this triagonist peptide that
confer high chemical stability while conserving native potency and efficacy. Furtheremore, these
and other peptide modifications that rely on side chain attachments open the door for the design
of further improved peptide hormone analogs that are specifically designed to facilitate access to
the brain and protect neuronal cells. Such compounds will provide candidate therapeutics that
can move into the translational pipeline, to be pursued in subsequent phase II studies that will
initially focus on developing a treatment for mTBI.
We will synthesize a library of peptides and select for high potency target receptor activation and
maximized access to the brain. Moving further through the screening funnel, candidates will be
further prioritized based on their ability to rescue neuronal cells from oxidative stress and
glutamate excitotoxicity–induced cell death, and based on drug-induced attenuation of microglial
neuroinflammation. The deliverable in phase I will be the identification of a lead candidate and a
backup compound. These molecules will provide the basis for future phase II studies to further
determine PK/PD, and to explore therapeutic effectiveness in behavioral studies with mouse
models of mTBI as a prelude to preclinical (and clinical) studies.PUBLIC HEALTH RELEVANCE STATEMENT
This project will create a library of designed peptides that will specifically allow for
modulation of stability against specific proteases;
pharmacokinetics/pharmacodynamics; blood-brain-barrier (BBB) penetration
while simultaneously retaining biological function at receptors that mediate
neuroprotection. Modified peptide therapeutics will be used to ameliorate mild
traumatic brain injury (mTBI), an increasingly common clinical indication in contact
sports and in military settings.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government